AISA Pharma Announces Upcoming Profervia® Data Presentations at AAN and EULAR

Profervia® impact on key Nav 1.7 pain channel to be presented at AAN Initial Positive Phase 2 data from RECONNOITER-1 Trial in Systemic Sclerosis patients with Raynaud’s Phenomenon to be presented at EULAR BOSTON, April 3, 2023 /PRNewswire/ — Aisa Pharma, Inc. a private, clinical-stage…

About the Author

has written 39256 stories on this site.

Copyright © 2010 Business and Corporate News.